Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells

BACKGROUND: Increasing evidence has convincingly shown that abnormal pre-mRNA splicing is implicated in the development of most human malignancies. Serine/arginine-rich protein kinase 1 (SRPK1), a key splicing regulator, is reported to be overexpressed in leukemia and other cancer types, which sugge...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Cuiying, Liu, Beichen, Wang, Huan-You, Wu, Lili, Zhao, Guimin, Huang, Chen, Liu, Yueping, Shan, Baoen, Liu, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609466/
https://www.ncbi.nlm.nih.gov/pubmed/36303126
http://dx.doi.org/10.1186/s12885-022-10158-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609466/
https://www.ncbi.nlm.nih.gov/pubmed/36303126
http://dx.doi.org/10.1186/s12885-022-10158-6

Ejemplares similares